LIXTE Biotechnology Expands Collaboration with MD Anderson Cancer Center
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
LIXTE Biotechnology announced it is expanding its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial with LIXTE's proprietary compound, LB-100, to treat ovarian clear cell cancer. The trial, which combines LB-100 with GSK's Dostarlimab to enhance the effectiveness of immunotherapy, was initiated in January 2024. A second trial site was added earlier this year at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. MD Anderson and Northwestern Medical Center plan to double the number of enrollments in the trial to 42 patients, after successfully attaining its initial target of 21 patients earlier this year. The Company also announced that it expects data to be presented from the trial on the initial 21 patients in the first half of 2026.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on LIXT
About LIXT
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LIXTE Biotechnology Partners with IBN to Enhance Cancer Treatment Awareness
- Strategic Partnership: LIXTE Biotechnology has partnered with IBN to leverage its investor-focused distribution network of over 5,000 media outlets, aiming to enhance the company's visibility in cancer treatment and attract more investor interest.
- Innovative Therapy: LIXTE's lead clinical candidate, LB-100, a PP2A inhibitor, is being evaluated in combination with existing chemotherapy and immunotherapy, aiming to improve treatment outcomes for cancer patients, particularly in ongoing trials for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
- Market Potential: By integrating scientific methods into established treatment frameworks, LIXTE seeks to expand the impact of current cancer therapies without necessitating changes to clinical practice, addressing the urgent market demand for new treatment options.
- Experienced Partner: With over 20 years of experience serving more than 500 clients and millions of social media followers, IBN is well-positioned to provide robust brand communication support for LIXTE, helping it stand out in the competitive biopharmaceutical market.
Continue Reading
Lixte Biotechnology Secures $4.3 Million Financing for Cancer Treatment Development
- Financing Scale: Lixte Biotechnology's $4.3 million registered direct offering, facilitated by Spartan Capital Securities, underscores market confidence in its cancer treatment development efforts.
- Unit Structure: The offering comprises 1,051,342 Common and Pre Funded Units priced at $4.09 each, with each Common Unit including one share of Common Stock and a Common Warrant with an exercise price of $3.96, enhancing investor participation.
- Use of Proceeds: The net proceeds are earmarked for general corporate purposes and working capital, ensuring Lixte's sustained development during clinical phases, particularly in trials for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
- Market Positioning: Lixte focuses on developing cancer therapies targeting novel biological pathways, with its lead compound LB 100 showing favorable tolerability and activity in clinical studies, further solidifying its market position in the biopharmaceutical sector.
Continue Reading